Oelisoa M Andriankaja1, James J Jiménez1, Francisco J Muñoz-Torres1, Cynthia M Pérez2, José L Vergara1, Kaumudi J Joshipura1. 1. Center for Clinical Research and Health Promotion, School of Dental Medicine, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico. 2. Department of Biostatistics and Epidemiology, Graduate School of Public Health, Medical Sciences Campus, University of Puerto Rico, San Juan, Puerto Rico.
Abstract
UNLABELLED: The effects of lipid-lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. OBJECTIVE: To assess the association of LLA use with high-sensitivity C-reactive protein (hs-CRP) and oral inflammation. DESIGN: Cross-sectional analysis using baseline data from 1300 overweight/obese participants aged 40-65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs-CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self-reported. Separate logistic models were performed for systemic and oral inflammation. RESULTS: In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self-reported LLA use. Sixty percent of the participants had elevated hs-CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL-C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs-CRP compared to LLA non-users (OR = 0.58; 95% CI: 0.39-0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non-users (OR = 0.62; 95% CI: 0.42-0.91). CONCLUSIONS: Lipid-lowering agents may reduce both systemic and oral inflammatory responses.
UNLABELLED: The effects of lipid-lowering agents (LLA) on reducing systemic and oral inflammation have not been evaluated. OBJECTIVE: To assess the association of LLA use with high-sensitivity C-reactive protein (hs-CRP) and oral inflammation. DESIGN: Cross-sectional analysis using baseline data from 1300 overweight/obeseparticipants aged 40-65 years, recruited for the ongoing San Juan Overweight Adults Longitudinal Study. Serum hs-CRP was measured by ELISA, gingival/periodontal inflammation was evaluated as bleeding upon probing (BOP), and LLA was self-reported. Separate logistic models were performed for systemic and oral inflammation. RESULTS: In all, 24% participants reported history of dyslipidaemia, of which, 50.3% self-reported LLA use. Sixty percent of the participants had elevated hs-CRP (>3 mg/dl) and 50% had high BOP (defined as at or above the median: 21%). After adjusting for age, gender, smoking, HDL-C, physical activity, diabetes, blood pressure medications, and percent body fat composition, LLA users had significantly lower odds of elevated hs-CRP compared to LLA non-users (OR = 0.58; 95% CI: 0.39-0.85). After adjusting for age, gender, smoking status, educational level, mean plaque index and percent body fat, LLA users had significantly lower odds of high BOP compared to LLA non-users (OR = 0.62; 95% CI: 0.42-0.91). CONCLUSIONS:Lipid-lowering agents may reduce both systemic and oral inflammatory responses.
Authors: J L Fleiss; M H Park; N W Chilton; J E Alman; R S Feldman; H H Chauncey Journal: Community Dent Oral Epidemiol Date: 1987-08 Impact factor: 3.383
Authors: Oelisoa M Andriankaja; Francisco J Muñoz-Torres; José Vivaldi-Oliver; Brian G Leroux; Maribel Campos; Kaumudi Joshipura; Cynthia M Pérez Journal: J Periodontol Date: 2018-05 Impact factor: 6.993
Authors: Danielle E Haslam; Liming Liang; Dong D Wang; Rachel S Kelly; Clemens Wittenbecher; Cynthia M Pérez; Marijulie Martínez; Chih-Hao Lee; Clary B Clish; David T W Wong; Laurence D Parnell; Chao-Qiang Lai; José M Ordovás; JoAnn E Manson; Frank B Hu; Meir J Stampfer; Katherine L Tucker; Kaumudi J Joshipura; Shilpa N Bhupathiraju Journal: BMJ Open Diabetes Res Care Date: 2021-08
Authors: Ahmed A Alhassani; Frank B Hu; Bernard A Rosner; Fred K Tabung; Walter C Willett; Kaumudi J Joshipura Journal: Br J Nutr Date: 2021-01-08 Impact factor: 3.718